{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:09:31Z","timestamp":1789448971764,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T00:00:00Z","timestamp":1453939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T00:00:00Z","timestamp":1453939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"European Commission Framework Programme VI","award":["FP6-LSHC-CT-2004-503426"],"award-info":[{"award-number":["FP6-LSHC-CT-2004-503426"]}]},{"DOI":"10.13039\/100004336","name":"The Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffman La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"The National Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The EBCC-Breast Cancer Working Group"},{"name":"The Jacqueline Seroussi Memorial Foundation","award":["2006 JSMF award"],"award-info":[{"award-number":["2006 JSMF award"]}]},{"name":"Prix Mois du Cancer du Sein","award":["2004 award"],"award-info":[{"award-number":["2004 award"]}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["SG05-0922-02"],"award-info":[{"award-number":["SG05-0922-02"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Belge Contre le Cancer","award":["SCIE 2005-27"],"award-info":[{"award-number":["SCIE 2005-27"]}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Le Cancer du Sein"},{"DOI":"10.13039\/501100005972","name":"Parlons-en!","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Grant Simpson Trust and Cancer Research UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10549-016-3690-6","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T09:10:26Z","timestamp":1453972226000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041\/BIG 03-04 MINDACT trial breast cancer"],"prefix":"10.1007","volume":"155","author":[{"given":"Giuseppe","family":"Viale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Slaets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke A.","family":"de Snoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van\u2019t Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel J. T.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Stork-Sloots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Dell\u2019Orto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annuska M.","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,28]]},"reference":[{"key":"3690_CR1","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3.2010"},{"issue":"25","key":"3690_CR2","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"2007","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007(25):5287\u20135312","journal-title":"J Clin Oncol"},{"issue":"31","key":"3690_CR3","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013","journal-title":"J Clin Oncol"},{"key":"3690_CR4","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784\u20132795","journal-title":"J Clin Oncol"},{"issue":"22","key":"3690_CR5","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-09-0449","volume":"15","author":"P Roepman","year":"2009","unstructured":"Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R et al (2009) Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15(22):7003\u20137011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3690_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13058-015-0643-7","volume":"17","author":"EA Perez","year":"2015","unstructured":"Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F et al (2015) The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. Breast Cancer Res 17(1):133","journal-title":"Breast Cancer Res"},{"issue":"15","key":"3690_CR7","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1200\/JCO.2007.13.6424","volume":"26","author":"SS Badve","year":"2008","unstructured":"Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M-L et al (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26(15):2473\u20132481","journal-title":"J Clin Oncol"},{"issue":"4","key":"3690_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/annonc\/mdu026","volume":"25","author":"G Viale","year":"2014","unstructured":"Viale G, Bogaerts J, Slaets L, Rutgers E, van\u2019t Veer L, Piccart-Gebhart MJ et al (2014) High concordance of protein (by IHC), gene (by FISH; HER2 only) and microarray readout (by TargetPrint) of ER\/PR\/HER2: results from the MINDACT trial. Ann Oncol 25(4):816\u2013823","journal-title":"Ann Oncol"},{"key":"3690_CR9","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1016\/j.ejca.2011.09.016","volume":"00","author":"E Rutgers","year":"2011","unstructured":"Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van\u2019t Veer L, Rubio IT et al (2011) The EORTC 10041\/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 00:2742\u20132749","journal-title":"Eur J Cancer"},{"key":"3690_CR10","unstructured":"Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van \u2018t Veer LJ, Rubio IT et al. Baseline results of the EORTC 10041\/MINDACT TRIAL (Microarray In Node 0-3 positive Disease may Avoid ChemoTherapy). ECCO 2013"},{"key":"3690_CR11","unstructured":"US Food and Drug Administration. Guidance for industry and FDA staff: Statistical guidance on reporting results from studies evaluating diagnostic tests. \n                    http:\/\/medical.cms.itri.org.tw\/pdf\/u14.pdf\n                    \n                   Accessed 13 May 2015"},{"key":"3690_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Meas 20:37\u201346","journal-title":"Educ Psychol Meas"},{"key":"3690_CR13","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1200\/JCO.2006.06.6944","volume":"24","author":"XJ Ma","year":"2006","unstructured":"Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611\u20134619","journal-title":"J Clin Oncol"},{"issue":"6","key":"3690_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/modpathol.2011.219","volume":"25","author":"JA Kraus","year":"2012","unstructured":"Kraus JA, Dabbs DJ, Beriwal S, Bhargava R (2012) Semi-quantitative immunohistochemical assay versus oncotype DX(\u00ae) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol 25(6):869\u2013876","journal-title":"Mod Pathol"},{"key":"3690_CR15","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","volume":"16","author":"TO Nielsen","year":"2010","unstructured":"Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222\u20135232","journal-title":"Clin Cancer Res"},{"key":"3690_CR16","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1200\/JCO.2011.34.7963","volume":"29","author":"DJ Dabbs","year":"2011","unstructured":"Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava R (2011) High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 29:4279\u20134285","journal-title":"J Clin Oncol"},{"key":"3690_CR17","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1200\/JCO.2009.24.8211","volume":"28","author":"FL Baehner","year":"2010","unstructured":"Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC et al (2010) Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 28:4300\u20134306","journal-title":"J Clin Oncol"},{"issue":"7","key":"3690_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","volume":"30","author":"T Iwamoto","year":"2012","unstructured":"Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ et al (2012) Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729\u2013734","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3690-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3690-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:11:48Z","timestamp":1589721108000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3690-6"}},"subtitle":["Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance"],"short-title":[],"issued":{"date-parts":[[2016,1,28]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3690"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3690-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,28]]},"assertion":[{"value":"28 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FS and LSS were employees for Agendia at the time of analysis. AG is an employee of Agendia. LV is a founder of Agendia and has stock ownership. All remaining authors have declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}